FDA Approvals in Oncology: October-December 2023
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
Author:
Cancer Research Catalyst Staff
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
In 2022, AACR launched a unique initiative called AACR Maximizing Opportunity for New Advancements in Research in Cancer (MONARCA)...
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
For the past five years, cohorts of talented young researchers from around the world have participated in the AACR...
For our readers who enjoy learning about the newest tools and strategies in cancer research, the second installment of...
As you prepare for trick-or-treating, check out the articles selected by the editors of the 10 AACR journals for...
Neuroblastoma, a rare cancer that occurs primarily in children, is a scientific paradox, said pediatric oncologist John M. Maris,...
AACR is a pioneer in the study of racial/ethnic and other disparities in cancer research and care. The 16th...
As the temperatures start to drop and the leaves begin to change color, enjoy the latest selection of studies...
FDA approvals issued in third quarter 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new...